KAPA

distress 7/10 · high distress / dilution risk

$0.30-6%today-85% from 52w high

kairospharma.com1 employeesFounded 2013Los Angeles, CABiotechnology

Lead: non-small cell lung cancer · est. market ~$35B (approx, global)

Revenue

pre-revenue

Liquidity

$4M

Runway

1.0 yrs

Shares 1y

+5%

Price & events

-62.1% over 6M

CatalystRating changeDilutionFinancingdashed = today

-5.6%

-13.1%

-30.8%

-55.8%

-61.2%

-69.8%

—

-88.6%

All

Overview

Market Cap: $6.33M
Volume: 275.21K
52 Week Range: $0.30 – $1.97
Total Shares: 21.41M
Float Shares: 13.42M
Short %: 1.07%
% Held by Insiders: 37.20%
% Held by Institutions: 6.94%
RVOL: 0.07x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Upcoming readouts & decisions · our signals

1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.

Catalyst news & presentations · 15

2026Guided 40%trial initiationsecondaryPhase 1CL-273 · First-in-human trials projected to commence in 2026.SEC 8-K
rest of 2026Guided 40%trial initiationsecondaryPhase 1CL-741 · Initiate Phase 1 studySEC 8-K
Q3 2026Guided 70%readoutPhase 1ENV-105 · Announce safety and efficacy resultsSEC 8-K
2026-07-16partnershipENV-105 · Entered into IIR agreement with Bayer for radium supply to study ENV-105 + XOFIGO in mCRPC bone metastases.SEC 8-K
2026-06-04partnershipCL-741 · Signed term sheet to acquire worldwide rights for CL-741.SEC 8-K
May 18-19, 2026conferencedata presentationsecondaryInvestor presentation at LD Micro InvitationalSEC 8-K
2026-03-02partnershipCL-273 · Entered binding term sheet to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics.SEC 8-K
2026-02-26partnershipSigned term sheet to acquire worldwide rights to CL-273 and CL-741 from Celyn Therapeutics.SEC 8-K
October 17–21, 2025conferencedata presentationsecondaryPhase 2ENV105 (carotuximab), apalutamide · Preliminary safety and clinical activity from Phase 2 study of apalutamide + carotuximab in advanced, castration-resistant prostate cancerSEC 8-K
2025-10-01partnershipTRC105, CD105 · Novation agreement with Tracon Pharmaceuticals transferring exclusive access to TRC105 and CD105 technologies from Enviro to KairosSEC 8-K
2025-10-01partnershipNovation agreement with Cedars-Sinai transferring exclusive license of two patents from Enviro to Kairos, effective April 17, 2025SEC 8-K
September 18, 2025 at 5 p.m. ETconferencedata presentationsecondaryPhase 2ENV105 · KOL event to discuss interim efficacy results from Phase 2 trialSEC 8-K
September 2025readoutPhase 2ENV-105 · Interim efficacy data from Phase 2 trial of ENV-105 in mCRPC.SEC 8-K
end of the second quarter 2025readoutPhase 2ENV105 · Safety and interim efficacy results discussion planned.SEC 8-K
2024-09-20partnershipENV105 · Bioassay services agreement with PreCheck Health Services to develop biomarkers and companion diagnostic for ENV105 in lung and prostate cancer trialsSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 21,411,198 · 3 offerings/1y · 0 PIPEs

2026-04-01424B3offering
2026-04-01424B3offering
2026-03-028-Kmaterial_agreement
2026-01-23EFFECTshelf_effective
2026-01-13S-3shelf_registration
2025-10-078-Kmaterial_agreement
2025-08-19424B3offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2025-11-19D. Boral CapitalBuy
2025-11-04D. Boral CapitalBuy
2025-10-20D. Boral CapitalBuy
2025-10-07D. Boral CapitalBuy
2025-09-19D. Boral CapitalBuy
2025-07-16D. Boral CapitalBuy

Competitors — non-small cell lung cancer

ABBVAbbVie Inc.$451.1B · D2
MRKMerck & Co., Inc.$318.8B · D3
NVSEFNOVARTIS AG$292.0B · D3
PFEPFIZER INC$142.2B · D3
REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
RVMDRevolution Medicines, Inc.$40.3B · D1
CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
MAIAMAIA Biotechnology, Inc.$78M · D5
AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.